Advancements in the Treatment of Atherosclerosis: From Conventional Therapies to Cutting-Edge Innovations

被引:1
作者
Liu, Yan [1 ,2 ]
Lu, Kuan [1 ]
Zhang, Ruru [2 ]
Hu, Dongliang [1 ,2 ]
Yang, Zhe [1 ]
Zeng, Jianfeng [2 ]
Cai, Wu [1 ]
机构
[1] Soochow Univ, Affiliated Hosp 2, Suzhou 215000, Peoples R China
[2] Soochow Univ, Ctr Mol Imaging & Nucl Med, Sch Radiol & Interdisciplinary Sci RAD X, State Key Lab Radiat Med & Protect,Collaborat Inno, Suzhou 215123, Peoples R China
基金
中国国家自然科学基金;
关键词
Atherosclerosis; Pharmacological therapies; Nanomedicine; Cardiovascular disease prevention; CORONARY-ARTERY-DISEASE; PLAQUE STABILIZATION; INTERVENTION; INFLAMMATION; MICE; RISK; REVASCULARIZATION; NANOPARTICLES; METABOLISM; COLCHICINE;
D O I
10.1021/acsptsci.4c00574
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Atherosclerosis is a leading cause of morbidity and mortality worldwide, driven by a complex interplay of lipid dysregulation, inflammation, and vascular pathology. Despite advancements in understanding the multifactorial nature of atherosclerosis and improvements in clinical management, existing therapies often fall short in reversing the disease, focusing instead on symptom alleviation and risk reduction. This review highlights recent strides in identifying genetic markers, elucidating inflammatory pathways, and understanding environmental contributors to atherosclerosis. It also evaluates the efficacy and limitations of current pharmacological treatments, revascularization techniques, and the impact of these interventions on patient outcomes. Furthermore, we explore innovative therapeutic strategies, including the promising fields of nanomedicine, nucleic acid-based therapies, and immunomodulation, which offer potential for targeted and effective treatment modalities. However, integrating these advances into clinical practice is challenged by regulatory, economic, and logistical barriers. This review synthesizes the latest research and clinical advancements to provide a comprehensive roadmap for future therapeutic strategies and emphasize the critical need for innovative approaches to fundamentally change the course of atherosclerosis management.
引用
收藏
页码:3804 / 3826
页数:23
相关论文
共 137 条
  • [11] Exosome-mediated delivery of inflammation-responsive Il-10 mRNA for controlled atherosclerosis treatment
    Bu, Te
    Li, Zhelong
    Hou, Ying
    Sun, Wenqi
    Zhang, Rongxin
    Zhao, Lianbi
    Wei, Mengying
    Yang, Guodong
    Yuan, Lijun
    [J]. THERANOSTICS, 2021, 11 (20): : 9988 - 10000
  • [12] Enhancing the human health and lifespan: a targeted strategy emphasizing statins
    Calabrese, Edward
    Pressman, Peter
    [J]. BIOGERONTOLOGY, 2024, 25 (05) : 883 - 890
  • [13] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [14] New Pharmacological Approaches to Target PCSK9
    Catapano, Alberico L.
    Pirillo, Angela
    Norata, Giuseppe D.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (07)
  • [15] Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    Chapman, M. John
    Le Goff, Wilfried
    Guerin, Maryse
    Kontush, Anatol
    [J]. EUROPEAN HEART JOURNAL, 2010, 31 (02) : 149 - 164
  • [16] Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting for the Treatment of Left Main Coronary Artery Disease
    Cho, Sang-Cheol
    Park, Duk-Woo
    Park, Seung-Jung
    [J]. KOREAN CIRCULATION JOURNAL, 2019, 49 (05) : 369 - 383
  • [17] Biomedical Advances in ABCA1 Transporter: From Bench to Bedside
    Choi, Hong Y.
    Choi, Senna
    Iatan, Iulia
    Ruel, Isabelle
    Genest, Jacques
    [J]. BIOMEDICINES, 2023, 11 (02)
  • [18] Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
    Dahlen, Amelia D.
    Dashi, Giovanna
    Maslov, Ivan
    Attwood, Misty M.
    Jonsson, Joergen
    Trukhan, Vladimir
    Schioth, Helgi B.
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [19] Unprotected Left Main Revascularization in the Setting of Non-coronary Atherosclerosis: Gulf Left Main Registry
    Daoulah, Amin
    Abozenah, Mohammed
    Alshehri, Mohammed
    Hersi, Ahmad S.
    Yousif, Nooraldaem
    Al Garni, Turki
    Abuelatta, Reda
    Almahmeed, Wael
    Alasmari, Abdulaziz
    Alzahrani, Badr
    Ghani, Mohamed Ajaz
    Amin, Haitham
    Hashmani, Shahrukh
    Hiremath, Niranjan
    Alharbi, Ahmad W.
    Kazim, Hameedullah M.
    Refaat, Wael
    Selim, Ehab
    Dahdouh, Ziad
    Aithal, Jairam
    Ibrahim, Ahmed M.
    Elganady, Abdelmaksoud
    Qutub, Mohammed A.
    Alama, Mohamed N.
    Abohasan, Abdulwali
    Hassan, Taher
    Balghith, Mohammed
    Hussien, Adnan Fathey
    Abdulhabeeb, Ibrahim A. M.
    Ahmad, Osama
    Ramadan, Mohamed
    Alqahtaniv, Abdulrahman H.
    Ahmed, Fatima Ali
    Qenawi, Wael
    Shawky, Ahmed
    Ghonim, Ahmed A.
    Jamjoom, Ahmed
    EI-Sayed, Osama
    Elmahrouk, Ahmed
    Elfarnawany, Amr
    Elsheikh-Mohamed, Nezar Essam
    Abumelha, Bader K.
    Shawky, Abeer M.
    Arafat, Amr A.
    Naser, Maryam Jameel
    Elmahrouk, Youssef
    Alhamid, Sameer
    Lotfi, Amir
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (01)
  • [20] Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets
    de Meyer, Guido R. Y.
    Zurek, Michelle
    Puylaert, Pauline
    Martinet, Wim
    [J]. NATURE REVIEWS CARDIOLOGY, 2024, 21 (06) : 379 - 395